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Abstract: Hepatocellular cancer (HCC) is a very fatal disease due to limited therapeutic options
as well as due to its association with underlying chronic liver disease in the majority of cases.
The immune evasion in HCC signifies a major barrier to the delivery of effective immunotherapy.
Sorafenib is the only Food and Drug Administration-approved drug available with an overall
response rate of 2%–3% and overall survival of 2.8 months. Chemotherapy has not been used
routinely because of the relative refractoriness of advanced HCC. The introduction of immune
checkpoint inhibitors (cytotoxic T-lymphocyte antigen 4, programmed death 1, and programmed
death-ligand 1) has opened a new horizon for cancer immunotherapy. Future direction in
immunotherapy for HCC is to rationally combine it with other treatment modalities, including
surgery, radiofrequency ablation, and cytotoxic agents, to maximize its therapeutic efficacy.
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Hepatocellular cancer (HCC) is a very lethal disease because of its association with
the underlying chronic liver disease in majority of cases. The treatment options are
also limited. Surgical resection is the preferred therapy; however, tumor extent and
underlying liver dysfunction make most patients ineligible for resection, leaving liver
transplantation as the only other curative alternative. The treatment modalities such as
radiofrequency ablation (RFA), transarterial chemoembolization, and systemic therapy
are considered in patients who are not candidates for curative option. However, indications are limited and may not be applicable in all settings. Sorafenib1 is the only Food
and Drug Administration (FDA)-approved drug available with an overall response
rate of 2%–3% and overall survival (OS) of 2.8 months. Chemotherapy has not been
used routinely because of relative refractoriness to chemotherapy of advanced HCC.
FDA approval of ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA4)-blocking antibody, in 2011, and nivolumab, a programmed death 1 (PD-1) inhibitor,
in 2014–2015, for patients with metastatic melanoma has opened a new horizon for
immunotherapy in cancer. Immunotherapy is now considered a main treatment option
for many solid and hematologic malignancies. Recently, immunotherapy including
CTLA-4 and PD-1 inhibitor has shown promising antitumor effects in HCC, a tumor
that is considered resistant to traditional forms of chemotherapy.

Role of cellular immune evasive mechanisms in HCC
The cancer immunogram has recently been proposed by Blank et al2 to better understand the interactions between cancer and immune system. The framework of this
19
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immunogram is built on seven parameters that determine the
effectiveness of immune system. These parameters include
1) recognition of tumor foreignness due to mutational load,
2) the immunological status of the patients, 3) the ability of
the immune cell to infiltrate into the tumor, 4) the inhibitory
state of the tumor microenvironment such as absence of
checkpoints, 5) absence of soluble inhibitors (interleukin 6
[IL-6], C-reactive protein), 6) absence of inhibitory tumor
metabolism (lactate dehydrogenase, glucose utilization), and
7) the tumor sensitivity to immune effectors, such as major
histocompatibility complex expression and interferon-γ
(IFN‑γ) sensitivity. The significance of these parameters may
differ greatly among the patients, with some factors being
more dominant than others. Because of the multifactorial
nature of cancer–immune interactions, combinations of
biomarker assays will be valuable to define the current states
of the cancer immunogram. This information will help guide
treatment choice both during natural cancer–immune interaction and upon immunotherapy. The intrinsic hepatic microenvironment has made it a relatively immune-tolerogenic
organ. Existing data describe multiple immune responses
that include modifications in the functional ability of immune
cells, change in cytokine level, and the expression of immune
receptor or ligand. These immune responses promote HCC
progression, therefore suggesting that antitumor immunity
may be restored with targeted therapies.
Liver sinusoidal endothelial cells, hepatic dendritic cells,
and Kupffer cells, by priming hepatic T-cell in the absence

of costimulation, serve as tolerogenic antigen-presenting
cells (APCs). This results in defective cytotoxicity and
immune tolerance.3,4 This function is very significant as
liver is persistently exposed to antigens absorbed from the
gastrointestinal tract.
The inability of the immune system to recognize liver
cancer cells is also explained by other proposed mechanisms.
These include increase in regulatory T-cell (Tregs), impairment of CD4+ T-cell functions, upregulation of immune
checkpoint pathways (CTLA-4, PD-1), suppression of natural
killer (NK) cells, and recruitment of immunosuppressive
cells, such as monocyte and neutrophils5–11 (Figure 1).
The immune hemostasis is maintained by CD4+CD25+
Tregs. Treg has an ability to suppress antitumor immune
responses. The preclinical models have shown that the deficiency of Tregs may exacerbate the autoimmunity-related
issues.12,13 The association of Treg and malignancies has also
been demonstrated in several studies.14,15 Similar increment of
Tregs was also observed in the peripheral circulation and the
tumor tissues of HCC patients.5 Shen et al16 and Kobayashi
et al17 further investigated their association with disease
progression and outcome. The poor survival was found to
be related to the upregulation of Treg that also leads to the
impairment of cytotoxic CD8+ T-cell.7,18,19
Myeloid-derived suppressor cells (MDSCs) symbolize a
diverse immunosuppressive cell population that is produced in
response to various tumor-derived cytokines. MDSC accumulation in peripheral circulation and within tumors is driven by

Myeloid-derived suppressor
cells (MDSCs)

CD4+CD25+Treg

Cancer-associated
fibroblasts (CAFs)
Tumor-associated
macrophages (TAMs)

Figure 1 Immune cells involved in tumor tolerance in hepatocellular cancer (HCC).
Abbreviation: Treg, regulatory T-cell.
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increased granulocyte macrophage colony-stimulating factor
(GM-CSF) levels produced by cancer cells.20 These cells are
in different stages of differentiation that constitute myeloid
progenitor cells, immature myeloid cells, immature granulocytes, monocytes, macrophages, and dendritic cells.21–23 The
MDSCs suppress the activity of effector T-cells and impaired
NK cell cytotoxicity and cytokine production.8,24 Hoechst et al
investigated the frequency and function of a CD14+HLADR−/low, a new population of MDSC in HCC patients. An
MDSC-mediated immune regulatory pathway was also identified in these patients. They proposed that the immunosuppressive function of MDSC is exerted through the induction
of CD4+CD25+Foxp3+ Tregs in cocultured CD4+ T-cells.24
Ilkovitch and Lopez25 suggested that liver MDSCs contribute to immunosuppression by interacting with Kupffer
cells, resulting in the upregulation of a negative T-cell costimulatory molecule, programmed death-ligand 1 (PD-L1).
In HCC patients who received RFA, MDSC has been found
to be correlated with tumor progression and prognosis. The
recurrence-free survival time was inversely associated with
post-therapy frequency of MDSC.26
NK cells represent an important cell type whose function is impaired in HCC patients.8 It has been suggested that
NK cells are inhibited by MDSC through NKp30 receptor.27
The induction of systemic immunosuppression by expanding CD14 (+) dendritic cells is another recently identified
mechanism in HCC, which may contribute to its progression. These regulatory cells suppress T-cell response by
CTLA-dependent IL-10 and indoleamine-2, 3-dioxygenase
production in HCC.28
The role of tumor-associated macrophages (TAMs) in
tumor microenvironment has also been studied. Recent
immunological evidence has recognized two distinct states
of macrophage activation that have exactly opposite roles in
tumor progression and metastasis. M1 macrophages counteract tumorigenesis by enhancing Th1 immunocyte responses
and activating other tumor-killing mechanisms. On the other
hand, M2 macrophages are immunoregulators, participate
in Th2 responses, and enhance tumor growth. TAMs have
recently been found to play a significant role in HCC progression and metastasis.29 It has been reported that TAMs decrease
antitumor immunity by suppressing T-cell function directly
by the expression of PD-L1 and therefore contributed to the
growth of HCC. Tumor-activated monocytes also secreted
cytokines that trigger the proliferation of pro-inflammatory
IL-17-producing CD8 (+) T-cells. These IL-17(+) cells are
accumulated in HCC and promote angiogenesis that results
in disease progression.30,31
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The high concentration of TAMs in surgically resected
HCC also has prognostic value. TAM was found to be a
predictor of poor outcome in most of the studies.19,32 The
peritumoral infiltration of neutrophils also has been shown
to enhance angiogenesis progression.33 There is also an
increasing evidence that cancer-associated fibroblasts (CAFs)
also promote tumorigenesis and metastasis by stimulating
angiogenesis, malignant cell survival, and proliferation.
CAFs are found in HCC with preexisting chronic hepatitis
and liver cirrhosis. These CAFs may be derived from the
activation of static fibroblast because of repeated inflammatory stimulation and tissue fibrosis. It is suggested that
during course of HCC progression, fibroblasts in peritumoral
tissue progressively convert into CAFs. This progression is
accelerated by tumor-secreted lysophostatidic acid, which
stimulates the recruitment of peritumor fibroblasts and their
differentiation into myofibroblasts.34,35

Immune checkpoint inhibitors
Cancer immunotherapy has been revolutionized by the discovery of two checkpoints, CTLA-4, and the programmed
cell death protein 1 pathway (PD-1/PD-L1; Figure 2). Immunotherapy against these negative immunologic regulators
has given new paradigm shift to immunotherapy and is now
considered a major component of cancer therapeutic modalities. CTLA-4 was the first negative checkpoint regulator to be
clinically targeted. Ipilimumab (an anti-CTLA-4 antibody)
showed a significant OS in patients with advanced melanoma
in randomized Phase III trial,36 which led to its approval by
the US FDA in 2011.
HCC-induced immune tolerance is associated with
multiple immunosuppressive mechanisms. HCC immune
tolerance is mediated through decreased costimulatory or
increased inhibitory checkpoint signaling that leads into
immunosuppression. Significant reductions in expression of
costimulatory molecules, such as B7-1 and B7-2, have been
identified in HCC cells,37 resulting in a decrease of B7/CD28mediated activation of effector T-cells. Immune-inhibitory
receptors and ligands also contribute a crucial role in the
maintenance of HCC immune tolerance. The CTLA‑4,28
PD-1 and its ligand (PD-L1),38 lymphocyte-activation gene
3 (LAG-3),39 Tim-3 (T-cell membrane protein 3) and its
ligand (galectin-9),40 and adenosine A2a receptor (A2aR)41
are among the several inhibitory checkpoints that have been
related with defective immune process in HCC.
LAG-3 is a molecule that has an inhibitory effect on
T-cell responses. Li et al39 demonstrated the correlation
between LAG-3 expression and HBV-specific CD8+ T-cell

submit your manuscript | www.dovepress.com

Dovepress

21

Dovepress

Raufi and Tirona
A
MHC

MHC

TCR

TCR

HCC
CD28

APC

T cell

PD-1
PD-L1

B7

CTLA

B
MHC

TCR

MHC

TCR

HCC
CD28

APC

T cell

PD-1
PD-L1

B7

CTLA
Tremelimumab

Nivolumab

Figure 2 Check point inhibition and hepatocellular cancer
Notes: (A) Interaction of CTLA-4 with B7 and binding of PD-1 with PD-L1 inhibit T-cell function resulting in tumor proliferation. (B) Antibody-mediated blockade of CTLA4 (tremelimumab) and PD-1 (nivolumab) enhanced T-cell function resulting in tumor death.
Abbreviations: APC, antigen-presenting cell; CTLA, cytotoxic T-cell lymphocyte antigen; HCC, hepatocellular cancer; MHC, major histocompatibility complex; PD-1,
programmed cell death-1; PD-L1, programmed cell death-ligand l; TCR, T-cell receptor.

malfunction. The upregulation of LAG-3 was found to cause
severe impairment in tumor-infiltrating CD8+ T-cells of HCC
patients. Li et al40 suggested the Tim-3/galectin-9 signaling
pathway as a potential immunotherapeutic target in patients
with HBV-associated HCC. Their work revealed that this
pathway mediates T-cell dysfunction, which leads to poor
prognosis in HCC patients. The glucocorticoid-induced
tumor necrosis factor receptor (GITR) and the inducible T-cell
costimulator (ICOS) are regulators (stimulatory checkpoint
molecules) of the immunosuppressive function of Tregs.
Pedroza-Gonzalez et al42 showed that GITR and ICOS are
upregulated in Tregs infiltrating HCC, and, therefore, suggested their role as a novel target for immunotherapeutic
interventions against tumor progression. In another study,43
they suggested that a combination of both GITR engagement
and CTLA-4 blockade can improve the antitumor immunity
by abrogating tumor-infiltrating Treg-mediated suppression
in HCC.
HCC-induced immune tolerance along with tolerogenic
hepatic environment and chronic inflammatory conditions
justify the use of these immune-targeting agents and checkpoint inhibitors alone or in combination with other treatment
modalities in HCC. They are now regarded as promising
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strategies in clinical development. Table 1 summarizes the
immune check inhibitors (CTLA-4, PD-1, and PD-L1) that
have been developed and being tested in clinical trials for
HCC. The clinical parameters of eligible patients used in
clinical studies for anti-CTLA-4 or anti-PD-1/PD-L1 treatment are mentioned in Table 2. This review is focused on the
role of these checkpoints and their antibodies relevant for the
treatment of patients with HCC.

Role of CTLA-4 in HCC and its
clinical implication and progress
The immune system plays an important role in identifying and eradicating classical highly immunogenic tumors,
such as melanoma. The tumor-associated antigens (TAAs)
expressed on transformed tumor cells activate the immune
system of the body. However, this alone is not sufficient for
the initiation of an effective response. The interaction between
antitumor T-cells and APCs is central to the development of
effective antitumor T-cell immunity. T-cell activation has a
complex mechanism that is modulated by stimulatory (cellsurface molecules CD28) and inhibitory CTLA-4 signals.
Their collaboration is critical for the coordination of effective immune system’s response to a tumor.44–46 Moreover,
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Table 1 Clinical trials on antibodies targeting PD-1 or PD-L1 in hepatocellular cancer
Antibodies

Class

Anti-cytotoxic T-lymphocyte antigen 4
Tremelimumab
Human IgG2
Tremelimumab
Human IgG2
Anti-PD-1
Nivolumab
Human IgG4
Nivolumab
Human IgG4
Nivolumab
Human IgG4
Anti-PD-L1
MEDI4736
Humanized IgG
MEDI4736
Humanized IgG

Phase

Monotherapy/combination

Trial ID

Status

II
I

Monotherapy
Chemoembolization and radiofrequency ablation

NCT01008358
NCT01853618

Completed
Recruiting

I
III
I

Monotherapy
Monotherapy vs sorafenib
Galunisertib

NCT01658878
NCT02576509
NCT02423343

Recruiting
Recruiting
Recruiting

I
I/II

Ramucirumab
Monotherapy and with Tremelimumab

NCT02572687
NCT02519348

Recruiting
Recruiting

Abbreviations: PD-1, programmed death 1; PD-L1, programmed death-ligand 1; Ig, immunoglobulin.

Table 2 Clinical parameters of eligible HCC patients for anticytotoxic T-lymphocyte antigen 4 or anti-programmed death 1/
programmed death-ligand 1 treatment
Subjects of 18 years or older (men and women)
Histologically confirmed advanced HCC
They are not eligible for surgical and/or locoregional therapies
They have progressive disease after surgical and/or locoregional
therapies
Eastern Cooperative Oncology Group performance status of 0–1
Dose escalation phase: Child–Pugh score of 7 points or less. Cohort 5:
Child–Pugh class B (B7–B8). For all other cohorts Child–Pugh score of
6 points or less
There is no history of autoimmune disease, any prior or current
clinically significant ascites, or any history of hepatic encephalopathy
Abbreviation: HCC, hepatocellular cancer.

CD28 facilitates and maintains a T-cell response. TAAs
presented in context with APCs bind with T-cell receptors
(TCRs). The B7 molecules on the APC surface bind with
CD28 receptors on the T-cell surface and their costimulatory
signal leads to the translation of TCR stimulation into T-cell
activation. This ultimate activation of T-cells induces T-cell
proliferation, cytokine secretion, and gene expression. These
T-cell-mediated antitumor immune responses are regulated by
inhibitory signals of CLTA-4 whose expression is upregulated
upon TCR stimulation. CTLA-4 prevents the costimulatory
signal by competing with CD28 for binding to B7 ligands
(CD80 and CD86) on the surface of APC because of higher
affinity and avidity.47 This binding inhibits the T-cell activation and proliferation through a homeostatic mechanism to
prevent autoimmunity under physiological conditions.48 The
CTLA-4-deficient mice die from lethal lymphoproliferation
as demonstrated in preclinical model.49
Unlike melanoma, magnitude of tumor-antigen-specific
T-cells in HCC patients is very limited.50,51 Flecken et
al50 demonstrated the immunodominance and functional
alterations of TAA-specific CD8+ T-cell responses in HCC.
The IFN-γ-producing CD8+ T-cells specific for TAA were
detected in the periphery as well as in liver and tumor t issue.

Cancer Management and Research 2017:9

Although these cells displayed clear immunodominance
pattern, no steady hierarchy was observed between different TAAs. The efficacy of such responses was functionally
limited as these TAA-specific CD8+ T-cells were found to
be impaired in their ability to produce IFN-γ.
Chen et al52 studied the role of CTLA-4 in a subcutaneous
murine hepatoma model. They demonstrated the enhancement of antitumor immunity by coadministration of CTLA-4
blockade, intratumoral GM-CSF microspheres, and thermal
ablation. Promising results of this observation were further
supported upon tumor rechallenge with this regimen. This
causes rejection of tumor rechallenge in 90% of treated mice
while cure of established distant tumor was observed in 50%
of the treated mice.
Sangro et al53 evaluated the efficacy and safety of antiCTLA-4 antibodies (tremelimumab) for the treatment of
HCC. Eligible patients include HCC patients with liver
cirrhosis (classified as Child–Pugh grades A and B) and
hepatitis C who were not the candidates of liver-directed
local therapy or had failed the standard of care for HCC. The
partial response was observed in 17.6% of patients (three out
of 17 assessable patients) per Response Evaluation Criteria
In Solid Tumors (RECIST) criteria, whereas disease control
rate was 76.4%. The recorded toxicity profile was tolerable
in the study. The patients most frequently developed skin
rash (65%), fatigue (55%), and anorexia (50%). A transient
elevation of serum transaminase activity was observed
only during the initial course of tremelimumab and was
not seen with subsequent cycles. Severe immune-mediated
adverse events were not recorded and, therefore, none of the
patients required the initiation of steroid. The study included
the most relevant group of patients (HCC with hepatitis C
virus [HCV]-related cirrhosis); however, results may show
differently in chronic HBV patients as far as safety profile
is concerned with relatively higher hepatic failure rates
than HCV because of frequent inflammatory flares in HBV
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patients, which may eventually result in variable tremelimumab-induced response.54 Nevertheless, the demonstration
of acceptable toxicity profile of tremelimumab in this study
provides the first evidence as one of the potentially new
therapeutic approaches of CTLA-4-targeted immunotherapy
in HCC patients.
The role of other alternative immunomodulatory molecules (Tim-3, PD-1, or LAG-3) has been studied to overcome
T-cell exhaustion during chronic viral infection.55,56

Role of PD-1/PD-L1 in HCC and its
clinical implication and progress
The promising results in targeting CTLA-4 in cancers such
as melanoma have attracted researchers to approach and target other immunologic checkpoints including PD-1/PD-L1.
PD-1 is an immune-inhibitory receptor that modulates the
activity of T-cells at different stages of the immune response
through interaction with its ligands, PD-L1 (B7-H1) and
PD-L2 (B7-DC).57–59
PD-1/PD-L1 is expressed on T-cells, activated B cells,
monocytes, Tregs, and NK cells. The PD-1/PD-L1 interaction
inhibits T-lymphocyte proliferation and functions (cytotoxicity, cytokine release), inhibits apoptosis of the tumor cells,
induces apoptosis of tumor-specific T-cells and promotes the
conversion of effector cells into Treg cells.60–62
Unlike CTLA-4 that modulates the immune responses
of early activation of naive and memory T-cells following
TCR engagement, PD-1 mostly inhibits effector T-cell activity in peripheral tissues in response to infection or tumor
progression.63
Limited data are available with respect to the preclinical
evaluation in HCC. Zabala et al10 evaluated the antitumor
effect of IL-12-based gene therapy on HCC occurring spontaneously in mice. A plasmid vector expressing IL-12 in a liverspecific and doxycycline-inducible manner was transferred
to the liver of L-PK/c-myc mice with HCC. Doxycycline
administration increased serum IL-12 and IFN-γ and induced
tumor lymphocytic infiltration resulting in tumor stabilization
or regression in less than half of all treated mice. The tumor
resistance in nonresponder mice was found to be correlated
to increase in Tregs and higher expression of the immuneinhibitory molecules, such as PD-1 and PD-L1. Willimsky et
al64 established a transgenic murine model of virus-induced
HCC by hepatocyte-specific adenovirus-induced activation
of the oncogenic SV40 large T antigen. They demonstrated
progressive local immune inhibition with considerably
greater T-cell infiltration in early-stage HCC compared with
that in advanced-stage HCC.
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PD-1/PD-L1 contributed to local tumor-antigen-specific
tolerance and was expressed in all CD8+ T-cells and HCC.
The expression of PD-1 by T-cells has prognostic relevance. Persistent expression is highly suggestive of an
exhausted phenotype resulting from a decrease in effector
function.65,66 Shi et al38 described circulating and intratumor
PD-1/PD-L1 expression and analyzed their association
with disease progression in HBV-infected patients. They
found out that the frequency of circulating PD-1+/CD8+
T-cells increased with disease progression. Moreover, PD-1
expression was found to be significantly increased in tumorinfiltrating effector CD8+ T-cells. The higher expression of
PD-1 was correlated with significantly poorer prognosis. Gao
et al67 investigated the expression of PD-L1 in human HCC
to define its prognostic significance after curative surgery.
Results showed that patients with higher expression of PD-L1
had a significantly poorer prognosis than patients with lower
expression. Multivariate analysis revealed tumor expression
of PD-L1 as an independent predictor for postoperative
recurrence. In addition, tumor-infiltrating cytotoxic and Tregs
were also found to be independent prognostic factors for both
survival and recurrence.
Recently, El-Khoueiry et al68 presented Phase I/II data of
patients with advanced HCC in American Society of Clinical Oncology (ASCO) 2015 annual meeting. The authors
demonstrated safety and antitumor activity of nivolumab,
a fully human IgG4 monoclonal antibody PD-1 inhibitor in
advanced HCC. Nivolumab was administered intravenously
every 2 weeks for up to 2 years. The dose range was from 0.1
to 10 mg/kg. Although there was a relatively small sample
study size of 42 patients, the results compare favorably with
the existing treatment options. Eleven patients had HCV
and 10 patients had HBV infection, while 50% of patients
were unaffected. Approximately 19% of patients (eight out
of 42 eligible patients) responded to nivolumab. Among
the responders, two patients achieved complete response,
while six patients had partial response. The responses to
nivolumab have been durable in 75% responding patients
(six out of eight) and were observed across all dose levels
and etiologic cohorts. Overall, approximately half of the
total evaluable patients (20 out of 42) had stable disease with
the longest-lasting 17 months. In addition, at 12 months,
62% of patients in the study were still surviving with HCC.
No maximum-tolerated dose was found. Treatment-related
adverse events of any grade occurred in 68% patients. Grade
3/4 adverse events were observed in 19% patients. The
most common (≥5% patients) grade 3 adverse events were
increases in aspartate aminotransferase (11%) and alanine
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a minotransferase (9%), while treatment-related grade 4
events consisted of elevated lipase (2%).
Sorafenib, a tyrosine kinase inhibitor, is currently the only
FDA-approved drug for advanced HCC. In comparison to
this agent in treating HCC, nivolumab showed promising and
encouraging OS results even in 70% patients who received
prior sorafenib therapy. The response rate was 19% with
nivolumab as compared to 2%–3% with sorafenib. There was
also 20% OS difference at 12 months (62% in patient with
nivolumab vs 42% with sorafenib). The patients with HCC,
including those with HBV and HCV infection, had manageable safety profile with nivolumab, and this safety profile was
similar to other tumor types treated with nivolumab. However,
these findings of nivolumab in HCC need to be validated in
a large randomized Phase III trial.

Conclusion
HCC is a lethal cancer with limited therapeutic options.
The immune evasion in HCC signifies a major barrier to the
delivery of effective immunotherapy. The introduction of
checkpoint regulators (CTLA-4, PD-1, and PD-L1) and their
blockade has opened a new horizon for cancer immunotherapy. Emerging data in HCC suggest that circumventing these
immunosuppressive pathways can lead to promising objective
clinical responses with acceptable toxicity profile. Future
direction in immunotherapy for HCC is to rationally combine
it with other treatment modalities, including surgery, RFA,
and cytotoxic agents, to maximize its therapeutic efficacy.
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